Adverse Events During Longterm Low-dose Glucocorticoid Treatment of Polymyalgia Rheumatica: A Retrospective Study
Authors:
- Maurizio MazzantiniMMMaurizio Mazzantini
- Claudia TorreCTClaudia Torre
- Mario MiccoliMMMario Miccoli
- Angelo BaggianiABAngelo Baggiani
- Rosaria TalaricoRTRosaria Talarico
- Stefano BombardieriSBStefano Bombardieri
- Ombretta DI MunnoOMOmbretta DI Munno
- 15 January 2012
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (3) , 552-557
Abstract
Objective. To assess the occurrence of adverse events in a cohort of patients with polymyalgia rheumatica (PMR), treated with low-dose glucocorticoids (GC). Methods. This was a retrospective study by review of medical records. Results. We identified 222 patients who had a mean duration of followup of 60 ± 22 months and a mean duration of GC therapy of 46 ± 22 months. We found that 95 patients (43%) had at least 1 adverse event after a mean duration of GC therapy of 31 ± 22 months and a mean cumulative dose of 3.4 ± 2.4 g. In particular, 55 developed osteoporosis, 31 had fragility fractures; 27 developed arterial hypertension; 11 diabetes mellitus; 9 acute myocardial infarction; 3 stroke; and 2 peripheral arterial disease. Univariate analysis showed that the duration of GC treatment was significantly associated with osteoporosis (p < 0.0001), fragility fractures (p < 0.0001), arterial hypertension (p < 0.005), and acute myocardial infarction (p < 0.05). Cumulative GC dose was significantly associated with osteoporosis (p < 0.0001), fragility fractures (p < 0.0001), and arterial hypertension (p < 0.01). The adverse events occurred more frequently after 2 years of treatment. Multivariate analysis showed that GC duration was significantly associated with osteoporosis (adjusted OR 1.02, 95% CI 1.02–1.05) and arterial hypertension (adjusted OR 1.03, 95% CI 1.01–1.06); GC cumulative dose was significantly associated with fragility fractures (adjusted OR 1.4, 95% CI 1.03–1.8). Conclusion. Longterm, low-dose GC treatment of PMR is associated with serious adverse events such as osteoporosis, fractures, and arterial hypertension; these adverse events occur mostly after 2 years of treatment.Keywords
This publication has 16 references indexed in Scilit:
- Incident Comorbidity Among Patients with Rheumatoid Arthritis Treated or Not with Low-dose Glucocorticoids: A Retrospective StudyThe Journal of Rheumatology, 2010
- Use of oral corticosteroids and the risk of acute myocardial infarctionAtherosclerosis, 2007
- Very low‐dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2005
- Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular DiseaseAnnals of Internal Medicine, 2004
- Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trialAnnals of the Rheumatic Diseases, 2004
- Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialAnnals of Internal Medicine, 2002
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study GroupRheumatology, 1998
- Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumaticaArthritis & Rheumatism, 1997
- The Effect of Glucocorticoids on Joint Destruction in Rheumatoid ArthritisNew England Journal of Medicine, 1995